Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

CCorvus Pharmaceuticals, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
C

Corvus Pharmaceuticals, Inc.

$10.53Close · Oct 9, 2026
  • Overview
  • Financial statements
  • Metrics
    • Revenue & profit
    • Revenue by segment
    • Launches
    • Revenue concentration
    • Margins
    • Contracted revenue
    • Off-balance-sheet commitments
    • Cash flow
    • Cash & debt
    • Earnings per share
    • P/E ratio
    • Share count & dilution
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • Insider Transactions
Loading financial graphs

Metrics

Revenue & profit
Revenue by segment
Margins
Contracted revenue
Cash flow
Cash & debt
Earnings per share
Share count & dilution

Metrics

See the amounts the company has committed to pay that its balance sheet does not record yet: leases it has signed that have not started, unconditional purchase and other contractual commitments, and the most it could have to pay under guarantees and credit backstops. Amounts are as the filing reports them at each balance-sheet date.Formula: Commitments = leases not yet commenced + purchase & other commitments + maximum guarantee exposure
201720172019202020212022202320242025202601M2M3M
      Latest period 2017. Purchase & other commitments 3.6M.
      Leases not yet commencedPurchase & other commitmentsGuarantees & contingent commitments
      Compare cash generated by the business, spending on long-lived assets, and what remains afterward.Formula: Free cash flow = operating cash flow − capital expenditures
      $
      2025201720182019202020212022202320242025-40M-30M-20M-10M0
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        • Capex: purchases of property, plant and equipment
        Latest period 2025. Operating cash flow -32.8M. Capex -174K. Free cash flow -33M.
        Operating cash flowCapexFree cash flow
        Compare the company’s cash cushion with its borrowings. Negative net cash means debt is greater than cash.Formula: Net cash = cash − debt
        2026201720182019202020212022202320242025020M40M60M80M100M
            Latest period 2026. Cash 18.9M. Debt 0.
            CashDebtNet cash
            Profit for each share over the trailing 12 months, adjusted for stock splits.Formula: Earnings available to common shareholders ÷ weighted-average shares
            $/share
            2025201720182019202020212022202320242025-3.00-2.00-1.000.001.00
              • Earnings period 2017-01-01 to 2017-12-31. Shares as of 2017-12-31: 21,041,250 source shares.
              • Earnings period 2018-01-01 to 2018-12-31. Shares as of 2018-12-31: 29,323,930 source shares.
              • Earnings period 2019-01-01 to 2019-12-31. Shares as of 2019-12-31: 27,953,233 source shares.
              • Earnings period 2020-01-01 to 2020-12-31. Shares as of 2020-12-31: 28,372,634 source shares.
              • Earnings period 2021-01-01 to 2021-12-31. Shares as of 2021-12-31: 46,553,511 source shares.
              • Earnings period 2022-01-01 to 2022-12-31. Shares as of 2022-12-31: 46,553,511 source shares.
              • Earnings period 2023-01-01 to 2023-12-31. Shares as of 2023-12-31: 49,038,582 source shares.
              • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 67,899,779 source shares.
              • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 74,696,629 source shares.
              Latest period FY 2025. EPS (TTM) -0.20.
              EPS (TTM)
              How much investors pay for each dollar of the company’s yearly earnings. It is not useful when the company has no profit.Formula: Share price ÷ trailing 12-month EPS
              2025201720182019202020212022202320242025-30x-20x-10x0x
                • Earnings period 2017-01-01 to 2017-12-31. Shares as of 2017-12-31: 21,041,250 source shares. Nearby weekly price on 2017-12-29.
                • Earnings period 2018-01-01 to 2018-12-31. Shares as of 2018-12-31: 29,323,930 source shares. Nearby weekly price on 2018-12-28.
                • Earnings period 2019-01-01 to 2019-12-31. Shares as of 2019-12-31: 27,953,233 source shares. Nearby weekly price on 2020-01-03.
                • Earnings period 2020-01-01 to 2020-12-31. Shares as of 2020-12-31: 28,372,634 source shares. Weekly price on 2020-12-31.
                • Earnings period 2021-01-01 to 2021-12-31. Shares as of 2021-12-31: 46,553,511 source shares. Weekly price on 2021-12-31.
                • Earnings period 2022-01-01 to 2022-12-31. Shares as of 2022-12-31: 46,553,511 source shares. Nearby weekly price on 2022-12-30.
                • Earnings period 2023-01-01 to 2023-12-31. Shares as of 2023-12-31: 49,038,582 source shares. Nearby weekly price on 2023-12-29.
                • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 67,899,779 source shares. Nearby weekly price on 2025-01-03.
                • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 74,696,629 source shares. Nearby weekly price on 2026-01-02.
                Latest period FY 2025. P/E ratio -35.8x.
                P/E ratio
                See how the number of shares changes over time. More shares can mean each existing share owns a smaller slice of the company.Formula: Outstanding shares = issued shares − treasury shares Share-count growth = (current shares ÷ previous shares − 1) × 100%
                2026201720182019202020212022202320242025020M40M60M80M
                    Latest period 2026. Shares outstanding 84.1M. Class detail unavailable 84.1M.
                    Class detail unavailable